Conference Presentations, Posters & Abstracts
—
Past Pharsight®
Contributions
2008
November
Falcoz C, Wang W, Ebling W, Claret L, Iyengar S, Gehlert DR, Kielbasa W. PKPD modeling of brain receptor occupancy from animal to man for establishing the clinical dose of the NK-1 Antagonist LY686017. [poster presentation]. Presented at: Pharmacokinetics UK 2008; November 26-28, 2008; London, UK. Posted with permission of sponsor.
Carrothers TJ, Fredrickson JO. The Benefits of Model-based Approaches to the Development of Anti-diabetic Compounds. [poster presentation]. Presented at: AAPS Annual Meeting; November 16-20, 2008; Atlanta, Georgia.
Chiu J, Chittenden J, Tsang YC. Development and Validation of an In Vitro / In Vivo Correlation (IVIVC) for Use in the Development of a Generic Drug. [poster presentation]. Presented at: AAPS Annual Meeting; November 16-20, 2008; Atlanta, Georgia.
Chittenden J, Chiu J, Tsang YC. Development and Validation of an In Vitro / In Vivo Correlation (IVIVC) Using Population Modeling and Meta-Analysis. [poster presentation]. Presented at: AAPS Annual Meeting; November 16-20, 2008; Atlanta, Georgia.
Weiner DL. Paving the Critical Path: Utilization of Model Based Drug Development for Improving the Efficiency of Clinical Drug Development. [keynote presentation].
Presented at: First Japanese Conference on Pharmacometrics (JCoP); November 15-16, 2008; Tokyo, Japan.
October
Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Staab A, Freiwald M, Bruno R, Stopfer P, Gatzemeier U, Von Pawel J. A Phase II Double-Blind Study to Investigate Efficacy and Safety of the Triple Angiokinase Inhibitor BIBF 1120 in Patients Suffering from Relapsed Advanced Non-Small Cell Lung Cancer. [poster presentation]. Presented at: International Thoracic Oncology Congress Dresen (ITOCD); October 1-5, 2008; Dresden, Germany.
Mouksassi S, Marier JF. Modeling and Simulation for Optimal Drug Development in Pediatric Populations. [invited presentation]. Presented at: 2nd World Conference on Magic Bullets (Ehrlich II); October 3-5, 2008; Nürnberg, Germany.
Messing B, Mouksassi S, Jeppesen PB, Joly F, Demchyshyn L, Cyran J, Marier JF. Pharmacokinetic / Pharmacodynamic Correlation Between Teduglutide, an Analog of GLP-2, and Citrulline, a Biomarker of Small Intestinal Enterocyte Functional Mass in Short Bowel Patients. [poster presentation P822]. Presented at: American College of Gastroenterology (ACG) Annual Meeting; October 3-8, 2008; Orlando, Florida.
September
Lukas J. Impact of Modeling and Simulation in Drug Development. [invited presentation]. Presented at: 30th Annual Congress of the Spanish Pharmacological Society (SEF); September 17-19, 2008; Bilbao, Spain.
Carrothers TJ, Khariton T, Rohatagi S. Performance Characteristics of Pooled Early Phase Concentration-QTc Modeling. [poster presentation]. Presented at: 37th Annual Meeting of the American College of Clinical Pharmacology (ACCP); September 14-16, 2008; Philadelphia, Pennsylvania.
Walker JR, Rohatagi S, Salazar DE, Dmuchowski CF, Shenouda M, Swearingen D, R. Basavapathruni R, Cuddy T, Field J, Marier JF, Samata N, Izumi T, Sarapa N. Thorough QTC Study with Rivoglitazone Confirms No Exposure-QTC Response Predicted by PK/PD Modeling of Pooled Phase I/II ECG Data. [poster presentation]. Presented at: 37th Annual Meeting of the American College of Clinical Pharmacology (ACCP); September 14-16, 2008; Philadelphia, Pennsylvania.
Zahir H, Rohatagi S, Falcoz C, Kshirsagar S, Khariton T, Mouksassi S, Wagg JK. Modeling and Simulation to Predict Optimal Doses of a Novel Fluoro-Quinolone, DC-159a in Healthy Subjects and Special Population. [poster presentation]. Presented at: 37th Annual Meeting of the American College of Clinical Pharmacology (ACCP); September 14-16, 2008; Philadelphia, Pennsylvania.
de Greef R, Maloney A, Olsson-Gisleskog P, Prins K, Schoemaker J, Panagides J.
Dose Selection of Asenapine: Application of Models Based on D2 Occupancy to Predict Efficacy and Safety. [poster presentation]. Presented at: 21st Congress of the European College of Neuropsychopharmacology (ECNP); August 30 - September 3, 2008; Barcelona, Spain.
July
Mouksassi MS, Chen C, Li J, Marier JF. PK/PD Modeling, Biomarkers and Clinical Endpoints: The Use of Cluster Analyses, Logistic Regressions, and Receiver Operator Characteristics (ROC) for Efficient Drug Development. [poster presentation]. Presented at: 9th World Congress on Clinical Pharmacology and Therapeutics (CPT); July 27-August 1, 2008; Quebec City, Canada.
June
Ezzet F. The Role of Literature-Based Disease Progression Models to
Support Knowledge Management and Decision-Making in Clinical Drug Development. [oral presentation]. Presented at: AAPS National Biotechnology Conference; June 22-25, 2008; Toronto, Canada.
Claret L, Stark FS, Sirzen F, Gieschke R, Bruno R. A modeling framework to simulate Xeloda dose intensity and survival in colorectal cancer. [oral presentation abstract]. Presented at: Annual Meeting of the Population Approach Group in Europe (PAGE); June 18-20, 2008; Marseille, France.
Claret L, Andre V, de Alwis D, Bruno R. Modeling and simulation to assess the use of change in tumor size as primary endpoint in Phase II studies in oncology. [poster abstract]. Presented at: Annual Meeting of the Population Approach Group in Europe (PAGE); June 18-20, 2008; Marseille, France.
Frances N, Claret L, Stark FS, Bruno R, Iliadis A. Modeling of longitudinal tumor size data in clinical oncology studies of drugs in combination. [poster abstract]. Presented at: Annual Meeting of the Population Approach Group in Europe (PAGE); June 18-20, 2008; Marseille, France.
Dunlavey M. Simplified Programming of Population Model User Interfaces. [poster presentation]. Presented at: Annual Meeting of the Population Approach Group in Europe (PAGE); June 18-20, 2008; Marseille, France.
Leary RH, Chittenden J. A Nonparametric Analogue to POSTHOC Estimates for Exploratory Data Analysis. [poster presentation]. Presented at: Annual Meeting of the Population Approach Group in Europe (PAGE); June 18-20, 2008; Marseille, France.
May
Kastrissios H. Communicating the Value of Pharmacodynamic Modeling in Drug Development. [invited presentation]. Presented at: Association of Regulatory and Clinical Scientists (ARCS) 17th Annual Congress; May 28-30, 2008; Sydney, Australia.
Rohatagi S, Heyrman R, Wang A, Carrothers T. Diurnally−Adjusted Trough: Peak Analysis of Diastolic Blood Pressure for a Fixed−Dose Combination of Amlodipine Besylate and Olmesartan Medoxomil. [poster abstract 377]. Presented at: American Society of Hypertension Annual Scientific Meeting and Exposition; May 14-17, 2008; New Orleans, LA.
Liang E, Tang MT, Kwei L, Korsan B, Green M, Poland B. Clinical Trial Simulation of Nicardipine versus Labetalol for Management of Hypertensive Emergencies in the Emergency Department Setting. [poster presentation]. Presented at: American Society of Hypertension Annual Scientific Meeting and Exposition; May 14-17, 2008; New Orleans, LA.
Poland B. Incorporating Adherence into Antiviral Clinical Trial Predictions. [invited presentation]. Presented at: Drug Information Association Workshop: Improving Drug Development Using Patient Adherence Data in Clinical Trials;
May 6-7, 2008; Washington, DC.
April
Poland B. Using in Vitro and Literature Data to Predict Effects of New Anti-Retrovirals. [invited presentation]. Presented at: ASCPT Annual Meeting; April 2-5, 2008; Orlando, Florida.
Venkatakrishnan K, Ezzet F, et al. LONGITUDINAL DOSE-RESPONSE ANALYSIS OF THE EFFECTS OF SIBUTRAMINE, ORLISTAT AND RIMONABANT ON BODY WEIGHT PROGRESSION IN POOLED OBESITY CLINICAL TRIALS: ILLUSTRATION OF KNOWLEDGE MANAGEMENT IN MODEL-BASED DRUG DEVELOPMENT. [poster abstract PII-45]. Presented at: ASCPT Annual Meeting; April 2-5, 2008; Orlando, Florida.
March
Bruno R, Claret L. On the Use and Value of Drug-Independent Survival Models to Support Clinical Drug Development in Oncology: Application of FDA's NSCLC Model. Quantitative Clinical Pharmacology: Critical Path Opportunities. FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology; March 18-19, 2008; Rockville, MD.
VanDenburgh AM, Shah MV, Wagg J, Khariton T, Hua S, Beddingfield FC, Brin MF, Abu-Shakra S. Clinically Meaningful Differences of the Ashworth Scale in Post-Stroke Upper Limb Spasticity. [poster presentation No. 1]. Presented at: Amercian Society for Experimental NeuroTherapeutics (ASENT) 10th Annual Meeting; March 6-8, 2008; Arlington, VA.
American Conference on Pharmacometrics (ACoP); March 9-12, 2008; Tucson, Arizona.
Corrigan B, Sweeney K, Trimble V, Sabry E, Sheardown H, Ahadieh S, Bergeron J, Carr J, Burke P, Suzuk Ai, Hoshiya M, Mitchell M, Taylor A, Chuang-Stein C, Barbee T, Ito K, French J, Tensfeldt T. Standardization of Data Collection for Literature Based Meta-Analyses: The Literature Information and Knowledge Explorer (LIKE) Initiative. [oral presentation].
Dykstra K, Hodge L, Carrothers TJ, Korsan B. Linking Modeling & Simulation, Decision Analysis, and the Technology of Drug Formulation. [poster presentation].
Ezzet F. Model-Based Literature Meta-Analysis: Virtues and Limitations. [oral presentation].
Korsan R. Cutting the Gordian Knot: Learn High Value Information Quickly for Better Decision-making. [oral presentation].
Mouksassi MS, Chen C, Marier JF. Dosing Strategies of Drugs with Narrow Therapeutic Windows: A simple Approach to Determine Trade-off Between Efficacy and Toxicity. [poster presentation].
Poland B. Equivalent Constant Concentration Summarizes Pharmacokinetics in HIV and HCV PK/PD Modeling. [poster presentation].
Rohatagi S, Song S, Khariton T, Carrothers TJ, Kuwabara-Wagg J, Kastrissios H. Role of Modeling and Simulation in Evaluating the QTc Prolongation Potential of Drugs. [poster presentation].
Rohatagi S, Haworth S, Ezzet F, Katrissios H, Carrothers TJ. Model Based Development of a Direct Factor Xa Inhibitor. [poster presentation].
Song S, Rohatagi S, Wickremasingha P, Khariton T, Kshirsagar S, Carrothers TJ, Kuwabara-Wagg J. Model Based Dose Selection of a Quinolone To Minimize Drug Induced Serum Creatinine Elevation. [poster presentation].
Stone J, Zajic S, Dykstra K, Al-Huniti N, Santora A, Ince A, Jin B, Denker D. Population PK/PD Modeling of Lumbar Spine Bone Mineral Density Response to 12 Months of Treatment with the Cathepsin K Inhibitor, Odanacatib, and Simulations to Further Evaluate the Dose-Response Relationship. [poster presentation].
Wickremasingha P, Rohatagi S, Falcoz C, Khariton T, Kshirsagar S, Kastrissios H, Carrothers TJ, Kuwabara-Wagg J. Population Pharmacokinetics and Exposure-Response Modeling and Simulation To Support Quinolone Phase IIA Dose Selection. [poster presentation].